Neuropsychopharmacology. 2011 Nov; 36 (12): 2431-2440.
Hoʻopukaʻia ma ka pūnaewele 2011 Jul 20. doi: 10.1038 / npp.2011.129
PMCID: PMC3194070
ʻO Alessandro Gozzi,1,2,* Michela Tessari,2 Lisa Dacome,2 Federica Agosta,2 Stefano Lepore,2 Anna Lanzoni,2 Patrizia Cristofori,3 Emilio M Pich,2 Mauro Corsi,2 a Na Hailaha Angelo1,2
Ua pili kēiaʻatikala i kuhikuhiʻia e nā mea'ē aʻe ma ka PMC.
Hōʻuluʻulu Manaʻo
Hoʻokahi pinepine ka lāʻau ketikona i ka mau hana hoʻokolohua ma kahi e aʻo ai nā rodents e hoʻokau pono iā lākou iho (SA) ka lāʻau. Eia nō naʻe, ʻaʻole maopopo ka nui o ka hoʻohālike ʻana o kēia mau hiʻohiʻona. Ua hoʻohana mākou i ka imaging résonance magnetic (MRI) e loiloi i ka hana basal a me ka hoʻokaʻawale ʻana i nā hana ʻōpala i nā kiʻekiʻu i kau ʻia ma kahi papa hana lōʻihi lōʻihi. Ma keʻano, ua ana mākou i ka nui o ke koko basebral (bCBV), kahi kikoʻī i hoʻokumu ʻia o ka metabolima basal, a me ka loiloi i ka ʻano o ka ʻōnaehana dopaminergic ma ke ʻano o ka hoʻomālamalama ʻana i ka pane o ka pharmacological MRI (phMRI) i hoʻoiho ʻia e ka dopamine-releaser amphetamine. Ua hōʻike ʻia nā kumuhana Cocaine i ka hōʻemi o ka bCBV i loko o nā wahi o fronto-cortical, nā nucleus accumbens, ventral hippocampus, a me thalamus. Ua hōʻike pū ʻia ka hui kokela i kahi pane hana i hoʻohui ʻia i ka amphetamine i loko o nā wahi ventrostriatal, kahi hopena e hoʻopulu nui ʻia ana me ka nui o ka kō o kokua. ʻO kahi pilina kū ʻole ma waena o ka bCBV i ka thalamus reticular a me ka pane o ka mua i hoʻopili ʻia e ka amphetamine i loaʻa i nā kumuhana hoʻomalu akā ʻaʻole i ka hui kokua, me ka hōʻike ʻana i ka interplay inhibitions i loko o kēia paikini attentional e hiki ke hoʻohuli ʻia e ka lāʻau lapaʻau. ʻO ka mea nui loa, ʻaʻole i hōʻike ka loiloi histopathological i nā loli nui o ka moe microvascular i loko o ka lolo o nā kumuwaiwai i hoʻomoʻa ʻia i ka popole, ke hōʻike nei i nā ʻike imaging ʻaʻole hiki ke hoʻopiʻi ʻia i ka pōʻino maʻi hoʻoneʻe kino. Kuhi kēia mau huaʻōlelo ʻo ia ka huaʻalā kākā, hōʻaia nui i ka cocaine SA i ka iole ka hopena o ka hoʻololi fonto fronto-cortical a striatal e hoʻolilo nei i ka hana neurobiological substrate no ka hōʻike o ke ʻano o ka hana paʻa ʻana i ka lāʻau lapaʻau.
Introduction
Hoʻohana ka cocaine cocaine i ka lōʻihi o ka hoʻololi ʻana o ka neurobiological i manaʻo ʻia e lilo i ka hoʻoheheʻe ʻana i ka mālama o ka mālama ʻana i ka lāʻau lapaʻau e wehewehe ana i ka hilinaʻi kokela.Koob ¶ AL, 1998). Ua hoʻomaka ka noiʻi neuroimaging kanaka i ke kukui i ke ʻano o kēia mau hoʻololi a me kā lākou pilina me nā ʻano kūpono a i ʻole nā hōʻailona. ʻO ka hoʻoneʻe mua frontostriatal a me ka metabolism i loko o ka nui o ka lawehala kokoti i hōʻike ʻia e nā mea noiʻi he nui (ʻO Strickland ¶ AL, 1993; London ¶ AL, 1999; Volkow ¶ AL, 1992). Ua hoʻopili ʻia ka hana hūnā ʻia o nā palena o mua i ka neʻe ʻana o ka neʻe neʻeneʻo a me ka mana o ka hopu ʻana i ka lāʻau lapaʻau e hoʻōla pinepine ʻia ai (ʻO Strickland ¶ AL, 1993; Kalivas, 2004). ʻO ka hoʻopaʻa haʻawina Positron emitter (PET) me ka koho D2 hōʻike nā dopamine (DA) i nā kumuhana me nā haʻalulu kokahi e hōʻike mau nei i ka hōʻemi ʻana o D2 Loaʻa kahi ʻĀwili (Volkow ¶ AL, 1993; Martinez ¶ AL, 2004) a hoʻemi i ka pane dopaminergic i loko o ka nucleus accumbens a me nā mea ʻē aʻe o ka 'circuit reward' (Volkow ¶ AL, 1997), pili pū me ka hoʻohaʻahaʻa ʻana i nā hoʻoikaika kūlohelohe i ʻike ʻia ma kēia mau kumuhana (Volkow ¶ AL, 2007). Ua hōʻike ʻia nā noiʻi hou loa i ka hoʻololi ʻia o ka pilina pili o nā nū catecholamine i lalo o ka pale ʻana o ka hana cortical i ʻike ʻia ma nā lawehala cocaine, kahi ʻike e hōʻike ana i nā ala hou no nā hana neuroadaptational e pili ana i nā mokuʻāina addictive (Tomasi ¶ AL, 2010; Gu ¶ AL, 2010).
Hoʻolaha pinepine ʻia ka kuhi cocaine i ka paradigms hoʻokolohua ma kahi i hoʻomaʻamaʻa ʻia nāole i ka lāʻau lapaʻau ponoʻī (SA) i ka lāʻau lapaʻau. Ma ka hoʻohana ʻana i nā hiʻohiʻona SA ʻē aʻe, ua hiki i nā mea hoʻomaʻamaʻa ke hōʻulu hou i kekahi mau hiʻohiʻona nui o ka hoʻohui ʻana i ka lāʻau lapaʻau, e komo pū ana i ka ʻimi ʻimi puʻu.Vanderschuren a me Everitt, 2004), ke noi ʻana i nā lāʻau lapaʻau ʻole (ʻO Ahmed a me Koob, 1998), a hoʻonui i ke kumu holo i ka lāʻau lapaʻau (Paterson a me Markou, 2003). ʻO kēia mau hiʻohiʻona e hana i kēia mau hana hoʻokolohua a me ke ʻano maikaʻi o ka maka e nānā i nā hanana neuroplastic e pili pū ana me ka hoʻohana ʻana i ka lāʻau lapaʻau ʻoliʻoli (ʻO Roberts ¶ AL, 2007). Eia nō naʻe, pili i nā lāʻau lapaʻau e pili ana i ka addiction cocaine, e like me ka kuleana blunted DA i nā wahi striatal i ʻike ʻia ma nā haʻawina ʻo PET (Volkow ¶ AL, 1993; Martinez ¶ AL, 2004), mai hoʻohālikelike kūpono ʻia e nā kuʻuna pōkole pōkole, hiki i ka cocaine SA paradigms, kahi kahi e noʻonoʻo ʻia ai (ie, hoʻonui ʻia) pane ʻia nā dopaminergic (Narendran a me Martinez, 2008). Eia kekahi, ʻike ʻole ka nui o kēia mau hoʻohuli ʻana i ka loli o ka neurofunctional hoʻololi i ʻike ʻia i nā hana neuroimaging kanaka.
I ka noiʻi ʻana i kēia manawa, ua hoʻohana mākou i ka imaging magnet resonance imaging (MRI) e kiʻi i ka hana basal a ʻokaʻeu i ka hana o ka lolo i ka hoʻohālikelike i ka cocaine SA. Ua hana ʻia kahi protocol (lōʻihi 52), ka lōʻihi o ke komo (12 h) SA protocol e hōʻike i nā hiʻohiʻona o ka maʻi kiʻekiʻe, hoʻomāino paʻakai i loko o nā kānaka (Gawin me Ellinwood, 1988; Briand ¶ AL, 2008). Ua hoʻolōʻihi ʻia nā manawa abstinence e hōʻemi i ka hopena o ke aʻalapona o ka lāʻau lapaʻau a me ka hōʻoia i ka hoʻomau mau ʻia ʻana e hoʻokau i nā wai kiʻekiʻe o ka cocaine (ʻO Roberts ¶ AL, 2007). Ma hope o ka manawa detoxification a 10 lā, ua ana mākou i ka nui microbal basal cerebral blood volume (bCBV), kahi hōʻailona kuhikuhi o ka hoʻomaha hoʻomaha o ka lolo (Gaisler-Salomon ¶ AL, 2009; uuku ¶ AL, 2004), a loiloi i ka hopena o ka ʻōnaehana dopaminergic ma ke kaohi ʻana i ka pane hana i ʻāpono ʻia e ka DA-releaser amphetamine me ka hoʻohana ʻana i kahi protocolology Mactacac MRI (phMRI) kumu ʻikepili (ʻO Gozzi ¶ AL, 2010; ʻO Schwarz ¶ AL, 2004). Kuhi ʻia ka hoʻoponopono ʻana ma waena o ka hoʻomaha ʻana (bCBV) a me nā pane o ka amphetamine-evoked (rCBV) i kahi hoʻāʻo ʻana e ʻike i ka disregulation i loko o nā kahe i mālama ka hoʻokipa a me ka hana no ka hoʻopihapiha i nā ʻāpana ʻekahi. Hope, pou-mortem ua lawe ʻia nā hoʻokolohua histopathological e nānā i ka hiki o ka hopena o nā hopena vascular a me ka neurotoxic o ka cocaine SA lōʻihi i nā ʻike imaging.
NĀ MEI A ME NĀ MANAʻO
Ua hoʻokō ʻia nā hoʻokolohua kūpono ma muli o nā hoʻoponopono Līlani e alakaʻi ana i ka pono holoholona a me ka pale. Ua nānā ʻia nā protocols e ke komite mālama holoholona mālama kaiāulu, e like me nā kuhikuhi a nā kumu o nā kumu manuahi o Laboratory Animal Care (NIH publication 86 – 23, loiloi 1985).
Cocaine SA
Apana hana no ka cocaine SA
Ua hoʻāʻo ʻia ka loina i hoʻoiho ʻia i ka cocaine SA i loko o nā lumi hoʻokele e like me ka mea i hōʻike mua ʻia nei (Moretti ¶ AL, 2010). Ua hoʻokomo ʻia kēlā me kēia keʻena hoʻokolohua (Med Associates, St Albans, VT) me kahi kukui cue i kau ʻia ma luna o kēlā me kēia kīhāpai, a me ke ʻano leo 2900-Hz. Ua hoʻohui ʻia kahi pā infusion ma o ka catheter o waho i kahi wai kūwaho wai kū hoʻokahi (Instech Laboratories, Plymouth Meeting, PA). Kāohi ʻia ka ʻikepili a me nā ʻōnaehana hoʻonohonoho-hoʻonohonoho i nā polokalamu Med-PC (Med Associates).
Palapala lawainu SA
Ka nui o 30 kāne Lister-Hooded rats (Charles-River, Margate, Kent, UK) i kaupaona ʻia ʻo 275 – 300 g nā home i hoʻopaʻa ʻia i loko o kahi pākeke-a me ka keʻokeʻo-kahe makani i mālama ʻia me ka wai i loaʻa. ponoʻole. ^ E Ha yM. Ua kaupalena ʻia nā holoholona ma ka hoʻokolohua e mālama ai i ke koʻikoʻi kino o ke kino o 300 g (± 10 g).
Ma hope o ko lākou hōʻea ʻana, hoʻopihapiha ʻia nā kiʻi no ka wiki 1 a laila hoʻoiho ʻia i kahi catheter i loko o ka jugular vein e like me ka mea i hōʻike mua ʻia (Moretti ¶ AL, 2010). Ma hope o kahi lā hoʻōla 7-lā, lawe ʻia nāʻiole i ke keʻena hana. Hoʻomaka ʻia ka hana ʻo Cocaine SA ma lalo o ka lakio paʻa (FR) 1 ka papahana hoʻoikaika. Hoʻopili kēlā me kēia kaomi ma ka lever hana me kahi infusion 0.1 ml o kahi hopena cocaine hydrochloride (3 mg / ml, e like me 300 μg no ka hoʻokomo a me 1 mg / kg i nāʻiole e kaupaona ana 300 g) me ka mālamalama like o ka stimulus (cue ) ka mālam a me ka luku ʻia o ke kukui keʻena no 20 s. ʻO nā kaomi ma ka lever 'ʻeleu' ʻaʻohe hopena i hoʻolālā ʻia. Ua ukali ʻia kēlā me kēia infusion lāʻau ('delivery reward') e kahi retraction lever 20-s. Ua hoʻopau ʻia nā kau ʻekolu 'hoʻomaʻamaʻa' mua ma hope o 50 infusions a i ʻole 2 h mai ka hoʻomaka o ke kau. I nā kau he 30 e hiki mai ana, ua hoʻonui ʻia ka manawa komo cocaine i 12 h (1800-0600 h), ua hoʻemi ʻia ka mahele lāʻau i 0.150 μg / infusion (0.1 ml o 1.5 mg / ml solution kokaine, e like me 0.5 mg / kg i nāʻiole. ke kaupaona ʻana 300 g), a me FR hoʻonui iki i 3 (kau 4-6) a ma hope i 5 (koena 27 mau kau).
ʻO nā mea i nalowale catheter patency a i ʻole hele kino ʻole (ʻo ia hoʻi, ua hōʻike i nā hōʻailona o ka maʻi) i neʻe ʻia mai ka noiʻi (11 kumuhana holoʻokoʻa). Hōʻike pinepine ʻia ʻo 48 – 72 h abstinence i nā lā 16 (session 14, 72 h), 23 (session 18, 72 h), a me 31 (session 23, 48 h) e hōʻemi i ka hopena o ka maʻa cocaine-induced intoxication. Ua ukali ʻia ka maʻi 30 e kahi lōʻihi (5 mau lā) binge abstinence i ukali ʻia i ʻelua mau manawa hou. Ua hoʻokomo ʻia nā ʻano like ʻole ma muli o ka pono o ka hoʻonohonoho ʻana i ka manawa MRI scan a me ka protocol SA ma luna o ka helu nui o nā kumuhana e hana ana. ʻO kahi manawa detoxification ʻo 10-lā i loko o ka hale home i hoʻokomo ʻia ma mua o ka hoʻokolohua imaging.
Ke kaʻina hana no SA
Ua hoʻohana ʻia kahi pūʻulu o nā makika 14 i kahi kikowaena papa kuhikuhi. Ua hoʻokomo ʻia nā kumuhana me kahi catularter jugular a ua hoʻomau ʻia ma ke ʻano aʻoaʻo a me nā kaʻina SA (me ka helu, ka lōʻihi o nā papa SA, a me ka pau ʻole) e like me ka mea i hōʻike ʻia ma luna nei, koe wale nō ka hoʻohana ʻana o ka kaʻa (saline, 0.1 ml) ma kahi o ka cocaine i ka wā o ka mea hana. nā hana.
Hoʻomākaukau Hoʻonā Hoʻohanohano
Hoʻomākaukau holoholona
Ua hana ʻia nā haʻawina loina 10 ma hope o ka hālāwai SA hope i hala. Ua hōʻike mua ʻia ka nui o ka hoʻomākaukau ʻana o ka holoholona a me nā ʻāpana MRI i kahi kikoʻī.ʻO Gozzi ¶ AL, 2010; ʻO Schwarz ¶ AL, 2004).). ʻO ka pōkole, ua loiloi ʻia nā lālani me 3% halothane, tracheotomized, a me ka nui o ka ʻenekini. ʻO ka wahī a me ka vein femoral a ke kālai ʻia nā holoholona a me D-tubocurarine. Ma hope o ka hōʻemi ʻana, ua hoʻonohonoho ʻia ka pae halothane i 0.8%. Mālama ʻia ke ʻano o ke kino o nā kumuhana āpau i loko o ka pae ʻana o ka physiological a me ke ʻano o ke kahe koko o ke kino (MABP) i kiaʻi mau ʻia e ka wahine femoral.
Loaʻa kiʻi kiʻi MR
Ua loaʻa nā manawa Anatomical a me fMRI ma kahi ʻōnaehana Bruker Avance 4.7 Tesla. Hoʻonohonoho ʻia nā holoholona i kahi kākoʻo paʻa i hana ʻia, a me kahi 'Rat Brain' curved quadrature two-loop loaʻa coil (Bruker, Ettlingen, Kelemānia) i kau ʻia ma luna o ka iwi poʻo holoholona a paʻa i ka mea paʻa holoholona. A laila hoʻopaʻa ka mea paʻa holoholona i kahi resonator manu manu 72 mm (Bruker) i hoʻohana ʻia no ka radiofrequency transmit wale nō. ʻO nā wili ʻelua nā mea maʻamau i hāʻawi ʻia e ka mea hana.
AT2-loaʻa i ka nui anatomical volume me ke ʻano he RARE (TR = 5461 ms, TEpau= 72 ms, RARE factor 8, FOV 40 mm, 256 × 256 matrix, 20 paleʻole 1 mm ʻoka) i ukali ʻia e ka loaʻa ʻana o kahi manawa-wa (TRpau= 2700 ms, TEpau= 111 ms, RARE factor 32, dt = 27) me ka kiko o ka lapalapa, e hoʻopuka ana i kahi kiko pixel nui o ≈1 mm3. ^ E Ha yM. Ka huina piha o ka mana MRI manawa-XMUMX (58 repetitions) no nā hui ʻelua.
Ma hope o ʻelima mau kiʻi kiʻi, ua 2.67 ml / kg o ka mea hoʻonaninani ʻo Endorem (Guerbet, Roissy CdG Cedex, Palani) i ʻōlelo ʻia no ke hoʻololi ʻana i ka hōʻailona fMRI ma ka pale ʻana i ke koko koko cerebral (rCBV) (Mandeville ¶ AL, 1998; ʻO Schwarz ¶ AL, 2003).). Ua mālama ʻia ka D-amphetamine (0.5 mg / kg) ma ka hana liʻiliʻi ma 25 ma hope o ka hoʻohālikelike ʻana o ka agent, a ua loaʻa ka ʻikepili MRI ma luna o kahi manawa o 25 minia ma hope o ka paʻakikī. ʻO ke koho o -amphetamine i koho ʻia ma mua I loko o ka ola nā haʻawina (ʻO Schwarz ¶ AL, 2004; ʻO Gozzi ¶ AL, 2011). Mālama ka lāʻau i ka hoʻoikaika ʻana o ka lolo, ʻaʻole hana i nā pane 'kaupaku' rCBV (Micheli ¶ AL, 2007), a hoʻoiho aku i nā pane MABP transient e uku ʻia i ka home ma ke ʻano o ka halothane anesthesia (ʻO Gozzi ¶ AL, 2007; Zaharchuk ¶ AL, 1999).
KaʻIkepiliʻIkepili
ʻO Basal CBV
Hoʻopili ʻia ka ʻike kiʻi kiʻi kiʻi kiʻi mākaukau ʻo bCBV no kēlā me kēia hoʻokolohua i loko o ka kaʻe o ke kumu hoʻohālike laina.Worsley ¶ AL, 1992).). Ua hoʻohiolo ʻia nā kumuhana pilikino i kahi stereotaxic rat MRI template set (ʻO Schwarz ¶ AL, 2006A).). Ua hoʻololi ʻia nā hoʻololi koʻikoʻi i nā bCBV (t) ma ka kumu pixel-akamai e like me ka wā i hōʻike mua ʻia (Chen ¶ AL, 2001; Mandeville ¶ AL, 1998).). Ua helu ʻia nā manawa bCBV ma luna o kahi hāmeʻa 4.5-min manawa e hoʻomaka ana me 6.8 min ma hope o ka hopena o ka inikua. Hōʻailona nā bCBV no nā kumuhana pākēneka e ka hoʻomohala ʻana i ka manawa manawa ʻo 10. Ua kau ʻia ka laina lōkuhi hoʻopuka no ka moʻo ʻana i ka holoi holoi ʻokoʻa (ʻO Schwarz ¶ AL, 2003).). Ua lawe ʻia ka helu pākuhi ʻo Voxel-akamai me ka hoʻohana ʻana i FSL (Smith ¶ AL, 2004) ka hoʻohana ʻana i ka inea multilevel Bayesian, me 0.7 mm spatial smoothing, a Z paepae> 1.6, a me kahi paepae koʻikoʻi o ka ʻōpili i hoʻoponopono ʻia p= 0.01.
pane leo phMRI i D-amphetamine
Ua hoʻololi ʻia nā hoʻololi hāliʻi MRI i ka CBV fractional (rCBV) e like me ka mea i hōʻike mua ʻia (Mandeville ¶ AL, 1998) a hoʻopiʻi ʻia e hōʻike i kahi kūʻokoʻa kūʻokoʻa mai ke kahe koko (ʻO Schwarz ¶ AL, 2003).). Hoʻokuʻu ʻia ka pauku manawa manawa rCBV no ka hoʻokūkū amphetamine i helu ʻia ma 12.5-min prechallenge a me ka puka aniani 24-min postchallenge. Ua lawe ʻia nā helu Voxel-akamai e hoʻohana ana i ka FEAT me ka 0.7 mm spatial smoothing a me ka hoʻohana ʻana i kahi hana hoʻohālikelike (Hoʻohui Kahi Uʻi S1) e hopu ana i ka ʻike pilikino o ka pane ʻana o ka RCBV amphetamine-induced (ʻO Schwarz ¶ AL, 2006b).). ʻO nā hoʻohālikelike hui kiʻekiʻe kiʻekiʻe i lawe ʻia ʻia me ka nānā ʻana o multilevel Bayesian a ua paepae ʻia ma ka Z> 1.6 me kahi paepae koʻikoʻi o ka cluster i hoʻoponopono ʻia o p= 0.01. I mea e hōʻike like ai i ka hypothesis o ka hoʻololi striatal hoʻololi i ka D-amphetamine i loko o nā mauʻu cocaine, ua hoʻāla ʻia ʻo 3D mask mask o kahi nui subortortical area (striatum, thalamus, hippocampus, hypothalamus the striatum, ventral pallidum, BNST, a me amygdala) kahi hoʻonohonoho hou kelepona o ka atlas utukole (ʻO Schwarz ¶ AL, 2006A) a hoʻohana i ka prethreshold rCBV manawa manawa ma mua o ke ʻano kiʻekiʻe FSL kiʻekiʻe kiʻekiʻe. Hoʻonui kēia kaʻina hana i ka mana helu o ka helu ʻana ma ka hōʻemi ʻana i ka helu o nā hoʻohālikelike he nui (Huettel ¶ AL, 2004).). E noiʻi i nā kikoʻī kūloko o ka hopena i kahi ʻano hoʻokaʻawale a hypotesa a hoʻokaʻawale i nā hoʻemi ʻana i ka nui o ka pane ʻana i ka amphetamine ma ke ʻano o ka lolo, ua hoʻohua ʻia ka hana like ʻana me nā kikoʻī data RCBV non-masked (Hoʻohui Kuhi S5). Ka nui o ka manaʻo (VOI) ka manaʻo o nā waiwai bCBV a me nā papa manawa no ka hoʻokūkū amphetamine i lawe ʻia e like me ka mea i hōʻike mua ʻia nei (ʻO Schwarz ¶ AL, 2006A; ʻO Gozzi ¶ AL, 2008). Ua helu ʻia nā ʻikepili helu ma mean bCBV me ka hoʻāʻo ʻana i hoʻokahi ANOVA hōʻike ma hope o ka hoʻāʻo ʻana a Fisher no nā hoʻohālikelike he nui.
Ka wehewehe hoʻoponopono
ʻO nā palapala o ka bCBV correlated a me D-amphetamine-induced rCBV pane ma waena o nā kumuhana i helu ʻia i loko o ka hoʻolālā GLM ma ka pae pūʻulu me ka kuhikuhi ʻana i ka bCBV i nā wahi wae e hoʻohana ana me FSL (ʻO Schwarz ¶ AL, 2007A, 2007b).). Ua koho ʻia kekahi helu o nā VOI e pili ana i nā hualoaʻa o nā palapala ma ka hui o ka intergroup bCBV (medial prefrontal, insular, orbitofrontal, somatosensory cortex, caudate putamen, nucleus accumbens, reticular thalamus, a posteroventral thalamus). No kēlā me kēia VOI, ua hoʻokomo ʻia ka hoʻomohala hoʻolālā i kahi regressor e hopu ana i ka pūʻulu e hōʻike ana i ka hōʻailona BCBV ma ka pae anatomical a me kekahi e pili ana i ka vector zero-mean veCtor ma waena o ka N nā kumuhana i ka hui mai ka hoʻonohonoho hoʻonohonoho koho i koho ʻia. O ka ZUa helu ʻia nā kiʻi me nā mea hoʻohālike e hopu ana i nā hopena maikaʻi a maikaʻi ʻole me ka pane kiʻi ʻana, a ua luhi ʻia me Z> 1.6 a me kahi paepae koʻikoʻi o ka cluster i hoʻoponopono ʻia o p= 0.01. Kuhi ʻia nā laina lohi o ka bCBV a me nā pane o ka RCBV i ka noʻonoʻo ʻana i ka bCBV a me ka pane ʻana o ka hopena RCBV i ka amphetamine ma waena o nā kumuhana pākahi, ʻo kēia ka mea i hōʻike ʻia ma ke ʻano he pane ma luna o ka minima 20 min (4-24 min postinjection).
Kauhauʻauhau
Ua hana ʻia ka loiloi mōʻauwai ma 10 koko kokahi a me 8 ka koho kaulima mua ʻana e like me ka mea i hōʻike mua ʻia (Barroso-Moguel ¶ AL, 2002).). Ma hope o ka hoʻokolohua MRI, mālama ʻia nā kaika ma lalo o ka puʻuwai hohonu (halothane 5%), a me ka hoʻōla a 15-min aortic perfusion o ka media fixative (10% buffered formalin) i hana ʻia, e hana ʻia e ka infusion 5-min. Ua hoʻoneʻe ʻia nā puʻuwai kūpono i mālama ʻia a mālama ʻia i ka hopena hoʻoponopono no ka 24-72 h. A laila ua hana ʻia ka trrain trrain ma ka hoʻohana ʻana i kahi matrix utukole (ASI Instruments) i hoʻolālā ʻia no nā kiʻi e kaupaona ana i 200-400 g. Nā huaʻehā o Tissue i hoʻopili ʻia, māhele ʻia i loko o nā ʻāpana aniani 5-μm-ipo, a paʻa ʻia me ka hui ʻana o ka hematoxylin-eosin a me ka Luxol Fast Blue (Scholtz, 1977).). ʻO ka wili a me nā wahi i hoʻopaʻa ʻia ʻo ka cortex cortex, caudate putamen, corpus callosum, hippocampus (C2), cerebellum (purkinje cells), a me nā substantia nigra. Hana ʻia ka hoʻokolohua e nā mea noiʻi manuahi ʻelua makapō manuahi.
Nā Hua
Kaoli Chaine SA
Ua hoʻopau nā pahuhopu āpau i nā hālāwai koina 33 cocaine SA ma kahi o 52 mau lā. Ua hoʻohana ka papa hana SA me kahi koina o ka cocaine i ka manawa holoʻokoʻa.Hōʻike 1).). ʻO ka awelika kumulative kumakai o SA cocaine ma ke kumuhana he 1138.4 ± 33.3 mg / rat. Hōʻike ʻia nā kaila ikaika a me ka ʻaina kokua i mea holoʻokoʻa i ka wā o ka hoʻokolohua, ʻoiai ʻo ke kaila linear i hōʻike ʻia kahi nāwaliwali a koʻikoʻi (p<0.03, F = 4.62) kū i ka hoʻonui ʻana o ka lawe ʻana i ka cocaine ma mua o ka manawa ke hoʻohālikelike ʻia nā kau like like (kau 4-31, FR 3-5, lawena abstinence binge 48-72 h) (Kaha Helu S2).
ʻO Basal CBV
Ma ke noiʻi ʻana i ka hopena o ka hoʻokō cocaine i ka hana basal utak, ʻike mākou i ka bCBV i ka cocaine SA a me ka kāohi ʻana i nā kumuhana a me nā ʻapoʻī i nā wahi e hōʻike ana i nā hōʻailona nui i waena o nā hui. Hōʻike ʻo Rats me ka cocaine SA i hōʻemi nui ʻia ka bCBV i kekahi mau wahi o ka lolo i hoʻohālikelike ʻia i nā kaole ʻōwili (Nā Hōkū 2 a A me3) .3).). Ka hopena i kaulana i ka medial-prefrontal, cingulate, orbitofrontal cortex, septum, ventral hippocampus, wahi nui o ka ulu ʻana o ka nucleus, a me nā pōpoki pīpī a me nā retalam thalamic area. ʻAʻohe ʻokoʻa o ka CBV āpau ma waena o nā hui i nānā ʻia (p= 0.23, Nā haumāna t-iūi). ʻAʻole i ʻike ʻia kahi koulou ma waena o ka bCBV a me ka piha o ka cocaine coca i nā VOI a pau.P> 0.16, nā VOI āpau).
Hōʻaliʻoniʻo ia i D-Amphetamine
I mea e hōʻoia ai i ka hoʻoneʻeʻana o ka dopaminergic striatal, ua ʻikea ʻia ka cocaine SA a me nā kaila ʻōpio me ka nui o DA-releaser amphetamine, a me ka ʻike ʻana i nā loli nui i ka nui o nā pane rCBV i kālele ʻia e ka lāʻau lapaʻau i loiloi ʻia ma o nā helu voxel-naau. E kū like me nā haʻawina mua (ʻO Schwarz ¶ AL, 2004), amphetamine hana hoʻōla ikaika o ka subortical a me nā ʻāpana cortical i nā pūʻulu ʻelua o nā kumuhana (Koho Hoʻohālike S3). Hōʻike pinepine ʻo Rats i ka cocaine i hōʻike i ka pane ʻana i ka amphetamine i ka striatum i hoʻohālikelike ʻia me nā kaole ʻōwili (Hōʻike 4 a me ke Koho Hoʻohui S3). ʻIke ʻia nā hopena ma nā kiko o ka manawa RCBV un-detrended (Hoʻohui Piha S4). I loko o nā kīkī i lawelawe ʻia ai i ka cocaine i mālama ʻia i ka nui o ka pane striatal i ka amphetamine i ʻike ʻia e inversely correlated me ka kumulamu kokola kumulamu (p= 0.03, Hōʻike 4).). Ua nānā ʻia nā kiko o ka hoʻoneʻe ʻana o ka pane hana kūpono i ka amphetamine i sensory-motor a me ka orbitofrontal cortex (Nā Koho Hoʻohui S3 a me S5).
Hoʻolālā ʻana i ka hoʻonui ʻana o ka amphetamine i hoʻonui ʻia i MABP (Ke Koho Koho S6). ʻAʻole i hoʻopili iki ka hopena me ka pane ʻana i ka hana, a maikaʻi hoʻi i loko o ke kahe autoregulatory koko ma loko o nā pane ʻana o vasopressive i uku homeostatically me ka ʻole o ka hoʻopuka ʻana i nā loli nui rCBV (ʻO Gozzi ¶ AL, 2007; Zaharchuk ¶ AL, 1999).). ʻO nā kahe koko arterial (paCO2 a paO2) i ana i ka mua a ma hope o ka manawa manawa fMRI (Koho Hoʻohui S1). ʻAʻohe mea ʻokoʻa lahilahi i ka ʻāmua mua a i ʻole post-acquisition paCO2 loaʻa nā waiwai ma waena o nā hui (p> 0.1, nā hui āpau; hoʻokahi ala ANOVA).
Ka Hoʻohui ma waena o ka hana Basal a me ka hana hewa
I ka hoʻāʻo ʻana e hoʻokumu i kahi correlation ma waena o ka hana basal a evased functionally a me ka noiʻi ʻana i nā dysregulations i ka hoʻokele ʻana o kēia mau moku ʻelua, ua uʻi mākou i ka pilina ma waena o ka bCBV a me ka pane o ka amphetamine-indicated ma ke kāohi a me nā holoholona e mālama pono i kā cocaine. ʻAʻole i loaʻa ka hopena ma waena o nā bCBV a me nā pane o ka rCBV amphetamine-induced i loaʻa i nā hui i kekahi o nā wahi i hoʻokolokolo ʻia, me ka ʻike ʻole ʻia o ka thalamus a reticular a posterior-ventral i hōʻike ʻia, i nā kumuhana paʻa, kahi pilina inikua me rCBV amphetamine-induced ma fronto -nā ʻāpana āpau (ʻAmelika Hoʻohui S7 a me S8). ʻAʻole nō kēlā me kēia haʻaheo i hana ʻia ma ka pūʻulu kokina (Supplement Figure S8).
Kauhauʻauhau
ʻO ka loiloi histopathological o ka umauma keʻokeʻo a me ka hina hina, nā wahi a me ka interstitial compartment, a me ka macro- a me micro-vascular, ependymal, a me ka hana meningeal ʻaʻole i hōʻike i kekahi mau neurocellular, interstitial, a i ʻole nā microvascular i nā hui pū kekahi. Ua hōʻike iki ʻole ʻia nā hōʻailona o ka pyknosis cellular a atrophy paha, hoʻololi ʻia ka leo, necrosis, a me interstitial edema i ʻike ʻia i kekahi o nā wahi o ka lolo e nānā ʻia, a me ka hoʻololi ʻia ʻana o ka moe microvascular a me ka capillary (ʻo ia hoʻi, ka basal membrane dilation a i ʻole rupture, hemorrhage, endothelial thickening a i ʻole wall fibrosis, thrombi or occlusions, and necrosis or vacuolation of endothelial cells).
KA HOOHOLO
ʻO nā palapala noi i kēia manawa ua loaʻa i ka cocaine paʻa mau ka nui o ka SA i ka iʻa ka hopena o ka loli neuroimaging e hoʻopili pili ana i nā ʻike kiʻi i loko o nā mea pili i kā cocaine. Kūʻai kūikawā, ua nānā mākou i ka hōʻemi o ka bCBV, kahi māka o ka hoʻomaha ʻana i ka hana noʻonoʻo, i nā wahi i loaʻa ke kōkua nui i nā hana cognitive kiʻekiʻe a me nā pale o nā neʻe (fronto-cortical areas), nānā a me ka manaʻo (fronto-hippocampal faritra), a me ka uku (mesolimbic wahi). Eia kekahi, pili ka cocaine SA i ka hoʻemi ʻana i ka striatal réactivity i ka hoʻoulu dopaminergic, a me ka hiki ʻana o nā hoʻololi pēpili putative i loko o ka pale o interplay ma waena o thalamus reticular a me ka hoʻōla ʻana o nā wahi fronto-cortical. Hāʻawi i kā mākou mau hopena neuroimaging e pili ana i ka nui o ka hoʻololi ʻana i ka hana o ka ʻoiole ma hope o ka ulu ʻana o ka kokela a me ka voluntary intake e hana ai i ka papa neʻe neʻe no ka hoʻohālikelike ʻana.
Hoʻomaʻamaʻa pinepine ʻia ka lāʻau kokoleka ma ka hanana paradigms kahi e aʻo ʻia ai nā rodents e hoʻokau i ka lawelawe ʻana i ka lāʻau lapaʻau. Maanei, ua hoʻokomo mākou i kahi protocol o ka cocaine SA wā lōʻihi a lōʻihi me ka manawa pīpī.Parsons ¶ AL, 1995; Wilson ¶ AL, 1994; ʻO Wilson lāua ʻo Kish, 1996) e kāohi i nā hiʻohiʻona o ka maʻi kiʻekiʻe, hōʻeha kino i ka loko o ke kanaka. Ua hōʻike ʻia nā paradigms SA lōʻihi i ka hana hou i nā hiʻohiʻona lapaʻau o nā ʻano hana kokoti me ka hoʻohana pū ʻana i ka lāʻau kūlohelohe ʻoiai ma ke ʻano o nā pilikia kūlohelohe.Vanderschuren a me Everitt, 2004), a kiʻekiʻe hoihoi e hoʻihoʻi i ka lāʻau lapaʻau ʻimi ʻona (ʻO Deroche-Gamonet ¶ AL, 2004).). Ka hana ʻole o ka protocol kūkaʻa (e uhi ana i ka ≈10% o ka lōʻihi o ka pālemakule o ka iole, Sharp a me La Regina, 1998) ʻae ʻia e hoʻohālikelike i nā heluna hoʻomanawanui me kahi mōʻaukala koʻikoʻi (> 6 mau mahina) o ka hōʻona ʻana o ka cocaine e like me nā mea i kākau inoa ʻia i nā noi neuroimaging kanaka, no laila ke hoʻonui nei i ka pili unuhi o kā mākou ʻike. Eia kekahi, ʻo ka hoʻohana ʻana o ke komo ākea ʻana i ka cocaine (ʻo ia hoʻi, h6 h) ʻike ʻia e hoʻohālikelike i nā hiʻohiʻona neurobeh behavioral kikoʻī o ka hoʻōla, e like me ka hoʻololi mau ʻana i nā hana noʻonoʻo (Briand ¶ AL, 2008; George ¶ AL, 2007), hoʻonui pana kumu no ka cocaine (Paterson a me Markou, 2003), a me ka neʻe i loko o ka hoʻohana i ka lāʻau (ʻO Ahmed a me Koob, 1998).). Ua hoʻolōʻihi ʻia nā manawa hana hoʻihoʻi i ka hōʻemi ʻana i ka hopena o ka hopena o ka lāʻau lapaʻau a me ka hōʻoia i ka hoʻomau mau ʻana i ka lawelawe ʻana i nā mana kiʻekiʻe o ka cocaine (ʻO Roberts ¶ AL, 2007).). ʻOiai ke kiʻekiʻe o ka kōnao kokoti i loaʻa me ka protocol o kēia manawa ua ʻoi aku ke kiʻekiʻe ma mua o ka mea e ʻike ʻia me ka loaʻa ʻole o nā paradigms pōkole.ʻAntslelo ¶ AL, 2004; Wee ¶ AL, 2007), e wehewehe ana i ka hemahema o ka lethality i nānā ʻia ma kēia noiʻi ʻana.
Hoʻohālikelike ʻia me nā protocols hoʻohana ʻole i ka mana, kahi i hōʻike ʻia ai ka hoʻohana ʻana i nā lāʻau lapaʻau ka nui a me ka haʻahaʻa o nā infusion i nā lā loli.Wilson ¶ AL, 1994), ke hoʻomohala nui o ka protocol e hoʻohana ʻia ma ʻaneʻi i hāpai ʻia ʻo SA o nā ʻano kiʻekiʻe o ka kokela. Kūlike ʻole i nā mea i hōʻike ʻia e nā hui ʻē aʻe (ʻO Ahmed a me Koob, 1998; Ferrario ¶ AL, 2005; Wee ¶ AL, 2007), ʻaʻole mākou i ʻike i nā hōʻike hōʻike kūlike o ka nui o ka pākōneka, ʻoiai naʻe he ʻano ka nui o ka komo ʻana i ka cocaine intake ma luna o nā hui i he mau lā.
ʻO kahi palena o ke k modelkohu e hana nei ʻaʻole ia i hoʻopili i nā ana o ka hoʻohana ʻana i ka lāʻau i loko o nā hopena maikaʻi ʻole (e like me, 'kūʻē i ka hoʻopaʻi' ʻO Deroche-Gamonet ¶ AL, 2004), he ʻano hana pono ʻia i manaʻo ʻia he koʻikoʻi diagnostic koʻikoʻi o ka hoʻohui ʻana i ke kanaka (AhahuiʻApelika Psychiatric Association, 2008).). No ka mea aia kēia hiʻohiʻona i ka ca. 20% o nā mea nui i ʻike ʻia i ka cocaine (ʻO Deroche-Gamonet ¶ AL, 2004; Ahmed, 2010), ke hoʻololi ʻia ka mea i hoʻololi ʻia ma ka hana i kēia manawa i ka hāʻawi ʻana mai nā kumuhana o nā kumuhana e hōʻike nei i kēia ʻano. Eia nō naʻe, eia ka hana a kēia mau hiʻohiʻona i nā hoʻololi maʻalahi i hoʻokaʻawale ʻia mai nā mea i manaʻo ʻia i kēia aʻo.
Ua kau ʻia kahi manawa holoi holoi 10 ma mua o ke aʻo ʻana i ka imaging aʻoi aku ka hopena o ka hopena o ka cocaine hopena a hoʻēmi ʻia i ka hopena o ke aʻole o ka pale ʻana i ka hopena o ka hana o ka lolo. ʻO ka hapa nui o ka hoʻololi ʻana o ka neurochemical a me ka hoʻonaninani e pili ana i ke kaila wili i loaʻa koke kahi hoʻomaka koke, ʻoki loa ma waena o 6 a me 72 h ma hope o ka pau ʻana o ka hoʻohana ʻana i nā lāʻau lapaʻau, a ʻoki ka hopena i loko o nā lā 2 – 7 mai ka lā i ka cocaine hope (Baumann lāua ʻo Rothman, 1998; ʻO Harris lāuaʻo Aston-Jones, 1993; Malin ¶ AL, 2000; ʻO Mutschler a me Miczek, 1998; Markou a me Koob, 1992).). A laila ʻaʻole hiki i nā loiloi imaging ke loaʻa ka perturbations nui mai nā hanana neilima e pili ana i ka hanana o ka cocaine kūloko. Ma ka ʻaoʻao ʻē aʻe, ʻike ʻia nā hoʻololi hana e ʻike ʻia mai nā hanana neuroadaptational lōʻihi (ʻo ia hoʻi, ka incubation o ka cocaine craving) i hōʻike ʻia e kūkulu nui ʻia ma hope o ka pau ʻana o ka kokua.Lu ¶ AL, 2004), a no ke ʻano o ka unuhi ʻana ma muli o ka hiki ke pili i ka propensity e hoʻohuli.
ʻAiʻi ʻo MRI o ka bCBV i ka hoʻokō ʻana i ka hakakā kiʻekiʻe i ka hoʻomaha ʻana i ka hana o ka lolo e hoʻopili paʻa ana me ka metabolism o ka ʻenekene a me nā kahe koko.Gaisler-Salomon ¶ AL, 2009; Kaukau ¶ AL, 2001; Gonzalez ¶ AL, 1995).). Hōʻike mākou i kā mākou ʻike i ka hōʻemi o ka bCBV hōʻemi i ka gyrus cingulated, cortex prefrontal, a orbitofrontal cortex, a me nā wahi striatal a me ka hippocampal mau kumuhana kokoleka SA. ʻO ka hopena frontostriatal i loko o ka ʻae like loa me ka noiʻi neuroimaging manuahi no ka hoʻohui ʻana i ka cocaine, kahi i mālama mau ʻia ai nā hana mua a me ka striatal.ʻO Strickland ¶ AL, 1993; Tumeh ¶ AL, 1990; London ¶ AL, 1999; Volkow ¶ AL, 1992, 1988) a ʻike ʻia e hui pū me ka hoʻopilikia cognitive, koi, a me ka nalowale o ka kaohi o ka pale ʻana i ka lawe ʻana i ka lāʻau lapaʻau e hiki ai i ka hoʻi hou aku (Goldstein ¶ AL, 2010; Kalivas ¶ AL, 2005; Kalivas, 2004; ʻO Hong ¶ AL, 2010; ʻO Strickland ¶ AL, 1993).). ʻO ka mea nui, nā nānā cognitive i nānā ma nā kiʻī i ʻae ʻia (ʻaʻole naʻe e kaupalena) ke komo ʻana i ka cocaine (Briand ¶ AL, 2008; George ¶ AL, 2007), he hanana e pili ana i ka hana hana a me nā hana nānā mau loa (ʻelua mau prefrontal cortex-hilinaʻi) a me nā hana e ʻike ai i ka hana (kahi hana hippocampus-hilinaʻi). Ke komo nei ka komo ʻana i nā ʻōnaehana hippocampal e like me ka hana a kēia ʻenehana i ka hanana ʻana a me ka hoʻomanaʻo ʻana, ʻelua mau hana e hoʻololi ʻia e ka cocaine a manaʻoʻiʻo ia ke hana i ka cue-elicited craving (loiloi ʻia e ka ʻO Koob a me Volkow, 2010).). Pēlā nō, hoʻoneʻe ʻia ka bCBV i ka nucleus accumbens i ʻike ʻole ʻia, hāʻawi ʻia ka pilina paʻa ma waena o ka hana fronto-cortical a me ka hana ʻana ma ka ʻai ʻana o ka selolostostrany DA.Kalivas ¶ AL, 2005; Nā lāhui ¶ AL, 2007).). Ke hoʻomau nei me kēia, nā hōʻike e pili ana i ka hana like ʻana o ka pēpē PET e hōʻike i nā pae haʻahaʻa o ka endogenous DA i ka mākeke cocaine pili i nā hoʻohālikelike kumuhana (Martinez ¶ AL, 2009) a me ka noiʻi haʻahaʻa hōʻike i hoʻemi ʻia ka hoʻohana ʻana i ka glucose i loko o nā wahi striatal ma luna o ka hoʻohana ʻana i ka cocaine hoʻohana, kahi ʻano i ʻoi aku ka nui o nā kūkā kokela.ʻO Porrino ¶ AL, 2007).
Ua nānā ʻia nā hoʻōla ʻana o nā bCBV i nā lula thalamic a me ka raphe nuclei. ʻO ka ʻike mua e pili ana i nā noiʻi neuroimaging kanaka e hōʻike ana i ke hoʻololi ʻia ʻana o ka lawehupena GABAergic i loko o ka thalamus o ka mea hoʻomake kokoti (Volkow ¶ AL, 1998) a me nā mea e pili ana i ka electrophysiological hōʻike o kahi kūlana overinhibition o nā retalam thalamic wahi ma hope o ka mālama ʻana i ka cocaine (Urbano ¶ AL, 2009).). ʻO ka mea mahalo, ʻo ka serotonin e hana i kahi hana kūlike a ka GABAergic neurons i ka reticular thalamus (McCormick a me Wang, 1991), ʻo ka hana hōʻemi o kēia mau nuclei a nānā i nā wahi o ka raphe i hiki ke hoʻopili pinepine ʻia a me kekahi hapa o ka pōkole pauahi.
ʻAʻole i loaʻa ka ʻikekelua ma waena o nā kōnao kokua a me ka bCBV i loaʻa i kekahi o nā VOI i hōʻike ʻia. ʻO ka nele o ka pili ʻana e hiki ke hōʻike i ka ʻokoʻa a ka pilikino i ka hopena o ka lāʻau lapaʻau, a i ʻole ka pili ʻana i ka nui o ka cocaine hoʻokaʻina kūʻokoʻa i ʻoi aku i ka nui o ka mea i koi ʻia e hana nui ai nā loli bCBV.
I ka hoʻāʻo ʻana e ʻike i kahi koina fMRI o ka hoʻopau i ka dopaminergic striatal i hōʻemi ʻia i ʻike ʻia i nā haʻawina aʻo kanaka (Volkow ¶ AL, 1990, 1993; Martinez ¶ AL, 2004), ua kiʻi pū mākou i ka pane hana i loaʻa e ka DA-releaser amphetamine me ka hoʻohana ʻana i kahi protocol phMRI (ʻO Schwarz ¶ AL, 2004; ʻO Bifone lāua ʻo Gozzi, 2010).). Ua hāʻawi ʻia kekahi mau haʻawina phMRI e hōʻike pono i ka pane striatal hemodynamic i hana ʻia e ka amphetamine e hōʻike pono ana i nā hopena dopaminergic (loiloi ʻia i loko Knutson a me Gibbs, 2007).). No ka hoʻohālikelike, ua hōʻike ʻia ka amphetamine i elicit BOLD a i ʻole ka rCBV i ka nui o nā wahi ma mua o nā ʻunana nui i loko o ka nui o ke ahonui a me ka pili o synaptic DA.Dixon ¶ AL, 2005; ren ¶ AL, 2009; ʻO Choi ¶ AL, 2006; ʻO Schwarz ¶ AL, 2007b; Hōʻailona ¶ AL, 2007).). Eia hou, ke hoʻopau ʻia nā pane rCBV amphetamine i koi ʻia ma nā wahi i loaʻa i ka DA.Chen ¶ AL, 1997, 1999), kahi hopena e hiki ke hoʻihoʻi hou ma hope o ka hoʻouluulu ʻana a ʻōlohelohe paha ʻoi.ʻO Bjorklund ¶ AL, 2002; Chen ¶ AL, 1999).). No laila, ʻo ka huina o kēia mau ikepili e hōʻike ana i nā pane o ka RCBV amphetamine-induced rCBV hiki ke hoʻohana pono i kahi hoʻohana ʻana i hōʻailona ma ka striatal DA neurotransmission. I loko o kēia papa hana, ka loaʻa ʻana o ka pane striatal rCBV stenatal e pili ana i ka amphetamine i ka hui kokoleka SA kokoleka e pili ana i ka emi ʻana o ka hana o ka hana dopaminergic ventrostriatal e like me nā mea i ʻike ʻia ma nā noiʻi PET i nā kānaka (Narendran a me Martinez, 2008). Hāʻawi kēia ʻike i ka manawa mua i kahi neuroimaging preclinical kūpono o kekahi o nā hōʻike loiloi loa o ka hoʻowalewale cocaine, ka mea i manaʻo ʻia he kuleana nui i ka 'hypohedonia' a me ka amotivation i hōʻike ʻia e nā kumuhana lāʻau ʻona i ka wā o ka haʻalele ʻana.Volkow ¶ AL, 1997). Kuhi kēia hopena i kahi leka koʻikoʻi koʻikoʻi ma waena o nā hoʻololi neuroadaptational klinikal a preclinical i hoʻokomo ʻia e ka cocaine ma nā ʻōnaehana DA, kahi hiʻohiʻona i ʻike ʻole ʻia e hoʻohālikelike ʻia e nā kūpale kūpuna cocaine, kahi e ʻike ʻia ai 'sensitized' (ie, hoʻonui) nā pane dopaminergic. (loiloi ʻia e Narendran a me Martinez, 2008).). Pēlā i ʻike ʻia ai nā pane striatal like ʻole i ʻike ʻia ma nā haʻawina neuroimaging rodent e hoʻohana ana i nā protocol protocol pohole (5 lā).Febo ¶ AL, 2005; Reese ¶ AL, 2004; a ʻo Gozzi, nā hualoaʻa i paʻi ʻole ʻia), hōʻike kā mākou data e, no kēia ʻano hana hoʻohālike i loko o ka rodents, hiki ke lōʻihi a loaʻa ke kīhāpai o nā koka. ʻO ka mea nui, ʻaʻole i nānā ʻia nā leʻaleʻa mikroskopika i nā hōʻiliʻili o ka vascular, neurocellular, a me interstitial of brains i ʻike ʻia i ka cocaine. He mea koʻikoʻi kēia hopena, no ka mea e ʻae ʻia e hāʻawi i kahi kōkua o ke kaʻina hana cerebrovascular abnormal ma luna o nā hemodynamic kaʻina o ka hana o ka lolo i hana ʻia (ʻo ia hoʻi, bCBV a me rCBV).
ʻO ka loiloi hoʻoponopono i waena o ka hoʻomaha a me ka amphetamine-evoked (rCBV) pane i hōʻike i kahi pilina kūlohelohe ma waena o bCBV ma nā wahi retalam thalamic a me ka hoʻālaʻi ʻana i mua o ka amphetamine i kahi kumumanaʻo, akā ʻaʻole ma ka hui kokua. Ua hōʻike ʻia nā haʻawina mua i ka pale ʻana o ka hana thalamic reticular e hiki ai ke hoʻonui i ka fronto-cortical dopaminergic neurotransmission (Jones ¶ AL, 1988), ka loaʻa ʻana me ka hoʻohui me nā hana pili o kēia mau ʻāina (Paxinos, 2008) a me ke kiʻekiʻe GABAergic kahakaha o ka reticular thalamic nucleus (Paxinos, 2008).). E like me nā mea hoʻokūkū mua i ka nucleus reticular thalamic e pāʻani nei i kahi kao kūʻokoʻa no ka hoʻokūkū kūloko.Zikopoulos lāua ʻo Barbas, 2006), ke kau nei mākou i ka nalowale o ka pilina ma waena o ke basal a me ka hana evaded i ʻike ʻia ma ka hui cocaine SA e pili ana me ka ʻike nui ʻole i ʻike i nā kiʻī i ʻae ʻia ke komo pono o ka cocaine (Briand ¶ AL, 2008; George ¶ AL, 2007).). ʻO ke kuleana koʻikoʻi no ka hana hakilima thalamo-mua i ka cocaine addiction ke kākoʻo ʻia e nā haʻawina neuroimaging hou e hōʻike nei i ka hoʻololi ʻana o ka thalamo-cortical hoʻololi i loko o ka cocaine abusers i lalo o ka hoʻomaha.Gu ¶ AL, 2010) a ke hana nei i ka hana kognitive (Tomasi ¶ AL, 2007).). Eia nō naʻe, no ka mea, ʻaʻole e hōʻike ka mea loulou i ka correlation isalation kumu, ʻike ʻia ka noiʻi e hoʻokaʻawale i ke ʻano maoli o kēia ʻike.
I ka hōʻākāka, hāʻawi mākou i nā hōʻike hōʻike o ka hana hoʻololi kino i loko o nā kahe e hele mau ana i ka cocaine SA lōʻihi. Kūkākūkā me nā ʻike neuroimaging haukapila, nā holoholona hūʻike i hōʻike ʻia i ka hoʻowalewale i ka hana basal ute ma nā wahi fronto-cortical a thalamic, a me ka hoʻokō ʻana i nā kuleana striatal i ka paʻakikī me ka DA-releaser amphetamine, he hopena i hoʻopili nui ʻia me ka huina o ka cocaine intake. ʻO ka hana maʻamau o kēia mau ʻike me nā hana neuroimaging i nā mea maʻi hoʻoleʻa kokela i kākoʻo i ka hoʻohana ʻana i nā paradigms SA lōʻihi a lōʻihi i loaʻa i nā kiʻina e ʻike ai i nā neuroadaptations i lalo o ka hoʻohui cocaine.
mau hoomaikai ana
Mahalo nui mākou iā Valerio Crestan lāua ʻo Giuliano Turrini no kā lākou kākoʻo loea maikaʻi loa i nā ana phMRI, a ʻo Pamela Rodegher mai Histolab, Verona, Italia, no ka hoʻomākaukau mōʻaukala.
Notes
ʻO nā mea kākau a pau nā limahana o GlaxoSmithKline. Hōʻike nā mea kākau, koe wale nō no ka loaʻa kālā mai ko lākou limahana mua, ʻaʻohe kākoʻo kālā a uku kālā paha i loaʻa mai kekahi ʻona a i ʻole hui pilikino ma mua o 3 mau makahiki i hala no ka ʻimi loiloi a me ka lawelawe ʻoihana a ʻaʻohe kuleana kālā pilikino i hiki ke ʻike ʻia ka hoʻokūkū ʻana o ka hoʻopaʻapaʻa hoihoi ʻana.
Nāʻaoʻao hemahema
Ua pili pū ka ʻike hoʻohui hoʻohui i ka pepa ma ka pūnaewele Neuropsychopharmacology (http://www.nature.com/npp)
Nā mea hou
Hōʻike Kuhi S1
Hōʻike Kuhi S2
Hōʻike Kuhi S3
Hōʻike Kuhi S4
Hōʻike Kuhi S5
Hōʻike Kuhi S6
Hōʻike Kuhi S7
Hōʻike Kuhi S8
Ke Koho Ukuʻi ʻia ʻOihana Pūnaewele
Ka Papa Hana S1
E hoʻomaopopo '
- Ahmed SH. Hōʻike pilikia i loko o nā hiʻohiʻona holoholona o ke hoʻohui ʻana i ka lāʻau lapaʻau: ma waho o ka hoʻohana ʻole ʻana i ka lāʻau lapaʻau ʻona e pili ana i ka hoʻohui lāʻau. ʻO Neurosci Biobehav Rev. 2010; 35: 172-184. [Hoʻokuʻuʻia]
- Ahmed SH, Koob GF. Ke hoʻololiʻana mai ke kūʻokoʻa i ka liloʻana i ka lāʻauʻawaʻawa: e hoʻololi i kahi hoʻonohonoho hedonic. ʻEpekema. 1998; 282: 298-300. [Hoʻokuʻuʻia]
- American Psychiatric Association 2000Diagnostic a me ka helu Manual o na maʻi noʻonoʻo (4th edn, kāhea ʻia). ʻAmelika ʻAmelika Hui Pū ʻIa: Washington, DC
- Barroso-Moguel R, Mendez-Armenta M, Villeda-Hernandez J, Nava-Ruiz C, Santamaria A. Brain lesions i hoʻoulu ʻia e ka maʻi kokoleka mākaʻi i mau kiʻo. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26: 59-63. [Hoʻokuʻuʻia]
- Baumann MH, Rothman RB. ʻO nā hoʻololi i ka pane ʻana i serotonergic i ka wā o ka hoʻoneʻe ʻana i ka cocaine i nā kiʻī: nā mea e like me nā kaumaha nui i loko o nā kānaka. ʻIollelo Bilo Psychiatry. 1998; 44: 578-591. [Hoʻokuʻuʻia]
- Bifone A, Gozzi A. 2010Functional a me ka lāʻau lapaʻau MRI ma ka hoʻomaopopo ʻana i ka hana o ka loloIn: Hagan J (ed) .Molecular a me Hoʻohālike Hoʻohālike ma Neuropsychiatry Springer
- Bjorklund LM, Saínchez-Pernaute R, Chung S, Andersson T, Chen IYC, McNaught KS, et al. Hoʻokomo nā pūlima stbryonic i nā neurons dopaminergic hana ma hope o ka hoʻololi ʻana i kahi hoʻohālikelike Parkinson. Manaʻo Natl Acad Sci USA. 2002; 99: 2344-2349. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Briand LA, Flagel SB, Garcia-Fuster MJ, Watson SJ, Akil H, Sarter M, et al. ʻO nā hoʻololi hou ʻana i ka hana cognitive a me ka prefrontal dopamine D2 receptors ma hope o ka hoʻonui ʻia ʻana, akā ʻaʻole kaupalena, ke komo i ka cocaine i hoʻokō ʻia. Neuropsychopharmacology. 2008; 33: 2969-2980. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, et al. ʻO ka ʻike o ka hana neuropansmitter dopaminergic e hoʻohana ana i ka MRI pharmacologic: ka hopena me ka PET, microdialysis, a me ka ʻike pili kino. Magn Reson Med. 1997; 38: 389-398. [Hoʻokuʻuʻia]
- Chen Y-CI, Brownell AL, Galpern W, Isacson O, Bogdanov M, Beal MF, et al. ʻO ka ʻike o ka pohō cell dopaminergic a me ka hoʻololi neural me ka hoʻohana ʻana i ka MRI pharmacological MRI, PET a me ka loiloi hoʻonaninani. NeuroReport. 1999; 10: 2881-2886. [Hoʻokuʻuʻia]
- Chen Y-CI, Mandeville JB, Nguyen TV, Talele A, Cavagna F, Jenkins BG. Hoʻonui ka hoʻomaikaʻi ʻana i ka lāʻau hoʻonaʻauao neʻe i ka lāʻau lapaʻau e hoʻohana ai i ka hana IRON me nā loina wai superparamagnetic. J Magn Reson Uihana Ana. 2001; 14: 517-524. [Hoʻokuʻuʻia]
- Choi JK, Chen YI, Hamel E, Jenkins BG. Hoʻololi nā maʻi hemodynamic i hoʻolōʻihi ʻia e ka dopamine receptors: ka hana o ka microvasculature cerebral i ka hoʻopili ʻia ʻana o ka neurovascular dopamine. Neuroimage. 2006; 30: 700-712. [Hoʻokuʻuʻia]
- ʻO Deroche-Gamonet V, Belin D, Piazza PV. Hōʻike no ke ʻano hoʻohālikelike-makemake i ka kahe. ʻEpekema. 2004; 305: 1014-1017. [Hoʻokuʻuʻia]
- Dixon AL, Mamua o M, Morris PM, Shah YB, Joseph MH, ʻ AMlelo AMJ. Dopamine antagonist modulation o amphetamine pane e like me ka hoʻohana ʻana me ka MRI pharmacological MRI. Neuropharmacology. 2005; 48: 236-245. [Hoʻokuʻuʻia]
- Febo M, Segarra AC, Nair G, Schmidt K, Duong TQ, Ferris CF. ʻO nā hopena neural o ka hōʻike hānai i hōʻike ʻia e ka MRI hoʻokūkū i nā kiʻiwe i ala. Neuropsychopharmacology. 2005; 30: 936-943. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Ferrario CR, Gorny G, Crombag HS, Li Y, Kolb B, Robinson TE. Neʻe a me ka hoʻonaninani palani pili i ka hoʻololi mai ke kāohi ʻia ʻana i ka hoʻohana kokua. ʻIollelo Bilo Psychiatry. 2005; 58: 751-759. [Hoʻokuʻuʻia]
- ʻO Gaisler-Salomon I, Schobel SA, SA SA liʻiliʻi, Rayport S. Pehea ke kiʻekiʻe o ka hoʻonāpaʻa ʻana i ke ʻano hana basal-state hiki ke alakaʻi i ka hoʻomohala ʻana o nā pharmacotherapies hou no schizophrenia. Kūleʻa Schizophr. 2009; 35: 1037-1044. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Gawin FH, Ellinwood EH. ʻO Cocaine a me nā mea hoʻoulu hou. N Engl J Med. 1988; 318: 1173-1182. [Hoʻokuʻuʻia]
- George O, CD Mandyam, Wee S, Koob GF. Hoʻopili ka hiki ke mālama i ka mālama cocaine hoʻōla i ka lōʻihi o ka hana hoʻomanaʻo ʻana o ka cortex-hilinaʻi. Neuropsychopharmacology. 2007; 33: 2474-2482. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Goldstein RZ, Woicik PA, Maloney T, Tomasi D, Alia-Klein N, Shan J, et al. ʻO ka methylphenidate wahaila i hoʻohālikelike i ka hana cingulate i ka hoʻohui ʻo cocaine i ka hana ʻoi nui. Manaʻo Natl Acad Sci USA. 2010; 107: 16667-16672. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Gonzalez RG, Fischman AJ, Guimaraes AR, Carr CA, Stern CE, Halpern EF, et al. Functional MR i ka loiloi ʻana o ka dementia: ka hoʻoponopono ʻana i ka nui o ke kīhāpai koko cerebral mau kino me nā loli i loko o ka cerebral metabolism ma ka positron emission tomography me fludeoxyglucose F 18. ʻO AJNR Am J Neuroradiol. 1995; 16: 1763-1770. [Hoʻokuʻuʻia]
- ʻO Gozzi A, ʻo Ceolin L, Schwarz A, Reese T, Bertani S, Bifone A. He noiʻi multimodality o ka haemodynamics cerebral a me ka autoregulation ma phMRI. ʻOihana Polokalamu Hoʻonani. 2007; 25: 826-833. [Hoʻokuʻuʻia]
- ʻO Gozzi A, ʻo Crestan V, Turrini G, Clemens M, Bifone A. Antagonism ma serotonin 5HT2a e hoʻohālikelike i ka hana hana o ka mokulele fronto-hippocampal. ʻĀpana Kauamai. 2010; 209: 37-50. [Hoʻokuʻuʻia]
- ʻO Gozzi A, Nui C, Schwarz A, Bertani S, Crestan V, Bifone A. Nā hopena ʻokoʻa o nā lawena antipsychotic a me ka glutamatergic i ka pane phMRI i ka hopena phencyclidine. Neuropsychopharmacology. 2008; 33: 1690-1703. [Hoʻokuʻuʻia]
- Gozzi A, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N, et al. Hōʻike i nā hana imon resonance magneto ʻokoʻa nā neural substrate no nā hopena o nā orexin-1 a me nā oragonin oracin-2 receptor. PLOSO HALE. 2011; 6: e16406. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- ʻO Gu H, Salmeron BJ, Ross TJ, Geng X, Zhan W, Stein EA, et al. Hoʻopilikia ʻia nā ʻōnaehana Mesocorticolimbic i nā mea kokua mākia e like me ka hōʻike ʻana ma o ka hoʻomau ʻana i ka hana hoʻomohala ʻana. Neuroimage. 2010; 53: 593-601. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- ʻO Harris G, ʻo Aston-Jones G. Beta-adrenergic antagonist e hōʻea i ka hopohopo i ka hopohopo i loko o ka mauʻu cocaine-a me nā kiʻi. ʻĀpana Kauamai. 1993; 113: 131-136. [Hoʻokuʻuʻia]
- Hong LE, Hodgkinson CA, Yang Y, Sampath H, Ross TJ, Buchholz B, et al. A ʻōhule hoʻoliʻiliʻi hou, kākoʻo ʻo ia i ka hoʻohui ʻana i ka nikotine kanaka. Manaʻo Natl Acad Sci USA. 2010; 107: 13509-13514. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Huettel S, Song AW, McCarthy G. Manaʻo Kākoʻo Hoʻōkoi Pūnaewele. Sinauer: Sunderland; 2004.
- Hyder F, Kida I, Behar KL, Kennan RP, Maciejewski PK, Rothman DL. Ka hana ʻana i ka hana hoʻonaninani o ka lolo: i ka hana ʻana i ka hana neuronal e BOLD fMRI. NMR Biomed. 2001; 14: 413-431. [Hoʻokuʻuʻia]
- Jones MW, Kilpatrick IC, Phillipson OT. Hoʻopilikia ka hana Dopamine i ka cortex prefrontal o ka pā i ka hōʻemi ʻana i ka tonic GABA-mediated inhibition i ka thalamic mediodorsal nucleus. Exp Brain Res. 1988; 69: 623-634. [Hoʻokuʻuʻia]
- Kalivas PW. Hoʻolaha nā ʻōnaehana glutamate i ka hoʻohui hoʻohui koko. Curr Opin Pharmacol. 2004; 4: 23-29. [Hoʻokuʻuʻia]
- Kalivas PW, Volkow N, Seamans J. Maʻa mau ke ʻano holoʻokoʻa i ka hoʻohui ʻana: he pathology ma prefrontal-accumbens glutamate transmission. Neuron. 2005; 45: 647-650. [Hoʻokuʻuʻia]
- Knutson B, Gibbs S. Ka hoʻopili ʻana i ka nucleus accumbens dopamine a me ka oxygenation koko. ʻĀpana Kauamai. 2007; 191: 813-822. [Hoʻokuʻuʻia]
- Koob GF, Sanna PP, Bloom FE. Hoʻomaʻamaʻa i ka hoʻohui ʻana. Neuron. 1998; 21: 467-476. [Hoʻokuʻuʻia]
- Koob GF, Volkow ND. ʻO ka neurocircuitry o ka hoʻohui. Neuropsychopharmacology. 2010; 35: 217-238. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- ʻO London ED, Bonson KR, Ernst M, Grant S. Brain imaging Studies of cocaine Abuse: implications for development drug. Crit Rev Neurobiol. 1999; 13: 227-242. [Hoʻokuʻuʻia]
- Lu L, Grimm JW, Hope BT, Shaham Y. Incubation o ka cocaine craving ma hope o ka haʻalele ʻana: he loiloi o ka ʻikepili preslinical. Neuropharmacology. 2004; 47: 214-226. [Hoʻokuʻuʻia]
- Malin DH, Moon WD, Moy ET, Jennings RE, Moy DM, Warner RL, et al. He kumu hoʻohālikelike o ka papahele o ka kokā. ʻO kahi laʻa ʻo Pharmacol Biochem Behav. 2000; 66: 323-328. [Hoʻokuʻuʻia]
- Mandeville JB, Marota JJA, Kosofsky BE, Keltner JR, Weissleder R, Rosen B, et al. Ka hana hoʻonaninani hana hoʻohālikelike o ka nui o ke koko cerebral i ka wā o ka paila forepaw stimulation. Magn Reson Med. 1998; 39: 615-624. [Hoʻokuʻuʻia]
- Mantsch JR, Yuferov V, Mathieu-Kia AM, Ho A, Kreek MJ. ʻO nā hopena o ka hiki ke hoʻonui aku i nā haʻahaʻa kokoleka kiʻekiʻe ma luna o ka hoʻokele pilikino, hoʻolaʻa hou ʻia ka cocaine-hoʻonaninani a me nā pae mRNA pae i nā kiʻi. ʻĀpana Kauamai. 2004; 175: 26-36. [Hoʻokuʻuʻia]
- Markou A, Koob GF. Huli hou ʻo Bromocriptine i ka kiʻekiʻe i loko o ka paepae hoʻōla ʻana me ka intracranial i nānā ʻia i loko o kahi ʻōhiole kaomi o ka huki kokō. Neuropsychopharmacology. 1992; 7: 213-224. [Hoʻokuʻuʻia]
- Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, et al. Ka neʻe Cocaine a me ka mea loaʻa o D2 e loaʻa i nā haʻawina hana o ka striatum: ka pilina me ka hana e noi ana i ka kokoti. Neuropsychopharmacology. 2004; 29: 1190-1202. [Hoʻokuʻuʻia]
- Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, et al. ʻO ka haʻahaʻa haʻahaʻa o ka dopamine endogenous i nā mea maʻi me ka hilinaʻi o ka cocaine: nā loaʻa mai ka PET imaging o D2 / D3 e pili ana i ka hoʻoneʻeʻana o ka dopamine akiki. Am J Kauhaiia. 2009; 166: 1170-1177. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- ʻO McCormick DA, Wang Z. Serotonin a me ka noradrenaline e hoʻihoʻi nei i ka neurones GABAergic o ka guinea-puaʻa a me ka puaʻa nū reticularis thalami. J Physiol. 1991; 442: 235-255. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, et al. 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series a potent and selektif dopamine D (3) receptor antagonists. J Med Chem. 2007; 50: 5076-5089. [Hoʻokuʻuʻia]
- Moretti M, Mugnaini M, Tessari M, Zoli M, Gaimarri A, Manfredi I, et al. A hōʻike hoʻohālikelike i nā hopena o ka intravenous self-administration or subcutaneous minipump infusion of nikotine ma ka hōʻike o ka uteʻo neuronal nicotinic receptor subtypes. Mol Halekola. 2010; 78: 287-296. [Hoʻokuʻuʻia]
- Mutschler NH, Miczek KA. Ke hoʻoneʻe nei mai kahi lawelawe hoʻonaninani a i ʻole a ʻole i ʻole e komo i ka kokoke kokahi: ka hopena i nā leo hōʻeha a me nā hopohopo ultrasonic i nā kiʻī. ʻĀpana Kaumanalima. 1998; 136: 402-408. [Hoʻokuʻuʻia]
- Narendran R, Martinez D. Cocaine hana hōʻino a me ka hoʻohaʻahaʻa ʻana i ka lawe ʻana o ka dopamine striatal: kahi loiloi koʻikoʻi o ka palapala hoʻoweliweli preclinical a me ka lapaʻau. Puʻipiʻi. 2008; 62: 851-869. [Hoʻokuʻuʻia]
- Parsons LH, Koob GF, Weiss F. Serotonin hana i loko o ke kinikona accumbens o nā lālani i ka wā i haʻalele ʻia ma hope o ka loaʻa ʻole o ka māhu intravenous. J Pharmacol Exp Ther. 1995; 274: 1182-1191. [Hoʻokuʻuʻia]
- Paterson NE, Markou A. Ua hoʻonui i ka hoʻowalewale no ka kokela mālama pono ʻia ma hope o ka pau ʻana o ka mālama kokua. NeuroReport. 2003; 14: 2229-2232. [Hoʻokuʻuʻia]
- Paxinos G. 2008Aa Hana Pūnaewele Nīkini Elsevier: Lādana; 1193pp.
- Peoples LL, Kravitz AV, Guillem K. ʻO ka hana o ka hypoactivity accumbal i ka hoʻohui koko. ʻĀpanaUnika. 2007; 7: 22-45. [Hoʻokuʻuʻia]
- Porrino LJ, Smith HR, Nader MA, Beveridge TJR. Nā hopena o ka niu: ʻo ke neʻe huli ʻana ma luna o ke kau me nā mea i hoʻohui. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 1593-1600. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- ʻO Preece MA, Sibson NR, Raley JM, Blamire A, Styles P, Sharp T. Region-effects effects of a tyrosine-free amino acid mix on amphetamine-induced hoʻololi in BOLD fMRI signal in the rat brain. Puʻipiʻi. 2007; 61: 925-932. [Hoʻokuʻuʻia]
- Reese T, Schwarz AJ, Gozzi A, Crestan V, Bertani S, Heidbreder CA. Nā kaʻina hana o ka hālāwai ʻumikūmeka ʻumikūmālua ISMRM a me nā hōʻike. ISMRM Press: Kyoto; 2004. Hōʻea nā hana imona résonance ʻano hopu i ka hoʻokaʻawale spatio-temporal ma waena o ka lāʻau-naive a me nā kiʻi amphetamine-sensitized; p. 228 pp.
- Ren J, Xu H, Choi JK, Jenkins BG, Chen YI. Pane Dopaminergic i ke kālele dopamine graded elicited e ʻehā o ka puhē amphetamine. Puʻipiʻi. 2009; 63: 764-772. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- ʻO Roberts DCS, Morgan D, Liu Y. Pehea e hana ai i ka mauʻu i hoʻohui ʻia i ka cocaine. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 1614-1624. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Scholtz CL. Kaʻāina helu kikowaena o ka myelin me ka hoʻohana ʻana iā Luxol Fast Blue MBS. Historochem J. 1977; 9: 759-765. [Hoʻokuʻuʻia]
- Schwarz A, Gozzi A, Reese T, Bertani S, Crestan V, Hagan J, et al. ʻO ka dopamine Dopamine D (3) reseptant antagonist SB-277011-A potentiates phMRI pane i ka hoʻonā amphetamine hopena i loko o ka puʻu rat. Puʻipiʻi. 2004; 54: 1-10. [Hoʻokuʻuʻia]
- ʻO Schwarz AJ, Danckaert A, Reese T, Gozzi A, Paxinos G, Watson C, et al. He papa palapala stereotaxic MRI i hoʻonohonoho ʻia no ka lolo ratile me nā papa kuhikuhi māhele o ka papa a me nā papa inoa anatomical i hoʻopaʻa ʻia: noi ʻia i ka MRI pharmacological MRI. Neuroimage. 2006a; 32: 538 – 550. [Hoʻokuʻuʻia]
- ʻO Schwarz AJ, Gozzi A, Reese T, Bifone A. Hōʻuluʻulu ʻia o ka hana i loko o ka lolo laikini hoʻōla i hoʻopaʻa ʻia: hoʻonā i nā ʻoihana e pili ana i nā pane pane i d-amphetamine. Magn Reson Med. 2007a; 57: 704 – 713. [Hoʻokuʻuʻia]
- ʻO Schwarz AJ, ʻo Gozzi A, Reese T, Bifone A. I ka hoʻomālamalama vivo o ka hoʻohui ʻana o nā hana ma nā polokalamu neurotransmitter e hoʻohana ana i ka MRI pharmacological MRI. Neuroimage. 2007b; 34: 1627 – 1636. [Hoʻokuʻuʻia]
- ʻO Schwarz AJ, Reese T, Gozzi A, Bifone A. Functional MRI e hoʻohana ana i nā mākaʻi intravascular: e hōʻalo ʻia ai ka papa cerebrovascular (rCBV) mau manawa. ʻOihana Polokalamu Hoʻonani. 2003; 21: 1191-1200. [Hoʻokuʻuʻia]
- ʻO Schwarz AJ, ʻO Whitcher B, Gozzi A, Reese T, Bifone A. ʻO ka loiloi cluster wavelet study-level data a me nā ʻōkuhi i hōʻike ʻia i loko o ka moʻo lāʻau ʻo MRI pharmacological MRI. J Nānaehana J Neurosci. 2006b; 159: 346 – 360. [Hoʻokuʻuʻia]
- PM PM Sharp, La Regina MC. 1998ʻO ka Labour Rat CRC Press: Berlin; 240 pp.
- Liʻi SA, Chawla MK, Buonocore M, Rapp PR, Barnes CA. Hoʻopili i ka hoʻoponopono ʻana i ka hana o ka lolo i nā mau kahe a me nā kiʻī e hoʻokaʻawale i kahi subregion hippocampal a ʻoi aʻe i ka hiki ke hele ʻia. Manaʻo Natl Acad Sci USA. 2004; 101: 7181-7186. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Ke holomua ma ka hana a me ke kaʻina hana kiʻi kiʻi MR a hoʻokō e like me FSL. Neuroimage. 2004; 23 (Hoʻonui 1: S208-S219. [Hoʻokuʻuʻia]
- Strickland TL, Mena I, Villanueva-Meyer J, Miller BL, Cummings J, Mehringer CM, et al. Pākuʻi Cerebral a me nā hopena neuropsychological o ka maʻi kokoleka e hoʻohana pono ai. J Neuropsychiatry Clin Neurosci. 1993; 5: 419-427. [Hoʻokuʻuʻia]
- Tomasi D, Goldstein RZ, Telang F, Maloney T, Alia-Klein N, Caparelli EC, et al. Thalamo-cortical dysfunction in cocaine abusers: pili i ka nānā ʻana a me ka noʻonoʻo. Psychiatry Res. 2007; 155: 189-201. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Tomasi D, Volkow ND, Wang R, Carrillo JH, Maloney T, Alia-Klein N, et al. Hoʻopilikia i ka hana hoʻopili paʻa me ka midbrain dopaminergic i ka poʻe hoʻomau kokoleka. PLOSO HALE. 2010; 5: e10815. [ʻO ka mea heluhelu piliʻole i ka PMC] [Hoʻokuʻuʻia]
- Tumeh SS, Nagel JS, English RJ, Moore M, Holman BL. He mau helehelena Cerebral i ka lawehala kokola: hōʻike ʻia e nā SPEK perfusion utak scintigraphy. E hana i ka holomua. Radiology. 1990; 176: 821-824. [Hoʻokuʻuʻia]
- Urbano FJ, Bisagno Vn, Wikinski SI, Uchitel OD, Llin RR. ʻO ka lawelawe ʻana o ka cocaine 'binge' i nā hopena i hoʻololi ʻia i nā pilina thalamocortical i nāʻiole. ʻO Biol Psychiatry. 2009; 66: 769-776. [Hoʻokuʻuʻia]
- Vanderschuren LJMJ, Everitt BJ. Ke ʻimi nei ʻo ia i ka lāʻau huina ma hope o ka hoʻomalu ʻana o ka mālama cocaine. ʻEpekema. 2004; 305: 1017-1019. [Hoʻokuʻuʻia]
- Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, et al. Hoʻopau i ka loaʻa o ka receptor dopamine D2 e pili ana me ka hoʻemi ʻana i ka metabolism mua e hoʻohiolo i ka hoʻomau i ka cocaine. Puʻipiʻi. 1993; 14: 169-177. [Hoʻokuʻuʻia]
- ʻO Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine i ka hōʻino ʻana i ka lāʻau lapaʻau a me ka hoʻoukaʻana: nā hopena o nā hana imaging a me nā hopena lapaʻau. Arch Neurol. 2007; 64: 1575-1579. [Hoʻokuʻuʻia]
- Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, et al. Nā hopena o ka hōʻeha kino o ka cocaine ma luna o nā receptor dopamine postynaptic. Am J Kauhaiia. 1990; 147: 719-724. [Hoʻokuʻuʻia]
- Volkow ND, Hitzemann RJ, Wang GJ, Fowler JS, Wolf AP, Dewey SL, et al. Hoʻomoe ka lōʻihi ma mua o ka lolo i ka hoʻololi ʻana i ka cocaine abusers. Puʻipiʻi. 1992; 12: 86. [Hoʻokuʻuʻia]
- ʻO Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K. Cerebral koko e holo nei i nā mākia kokoleka ma kahi ʻano ninaninau. Br J Psychiatry. 1988; 152: 641-648. [Hoʻokuʻuʻia]
- Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Gatley SJ, Dewey SS, et al. Hoʻohui ka paila ʻana i nā benzodiazepines i nā kumuhana hoʻomāne i ka cocaine. Am J Kauhaiia. 1998; 155: 200-206. [Hoʻokuʻuʻia]
- Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, et al. Hōʻemi ka striatal dopaminergic pane i nā kumumanao hilinaʻi i ka cocaine. Kalua. 1997; 386: 830-833. [Hoʻokuʻuʻia]
- Wee S, ʻO Spio SE, Koob GF. Nā hopena o ka pākiha a me ka kau ʻana ma ka cocaine-noho hoʻokele ma nā iole. J Pharmacol Exp Ther. 2007; 320: 1134-1143. [Hoʻokuʻuʻia]
- Wilson JM, Kish SJ. ʻO ka transporter vesicular monoamine, i ka ʻokoʻa i ka transporter dopamine, ʻaʻole ia e hoʻololi ʻia e ka maʻi kokoti mālama ponoʻī i ka kiʻī. J Neurosci. 1996; 16: 3507-3510. [Hoʻokuʻuʻia]
- Wilson JM, Nobrega JN, Carroll ME, Niznik HB, Shannak K, Lac ST, et al. He palena hoʻohālikelike subregional hortogeneous o 3H-WIN 35,428 a me 3H-GBR 12,935 ka hoʻohālikelike ʻia ʻana o nā mākēhi mālama ponoʻī. J Neurosci. 1994; 14: 2966-2979. [Hoʻokuʻuʻia]
- Worsley KJ, Evans AC, Marrett S, Neelin P. He helu helu helu ʻekolu ʻekolu no ka noi ʻana o CBF i ka hana naʻauao i loko o ka lolo o ke kanaka. J Cereb Kahe Kaha Kaila. 1992; 12: 900-918. [Hoʻokuʻuʻia]
- Zaharchuk G, Mandeville JB, Bogdanov AA, Jr, Weissleder R, Rosen BR, Marota JJ. He dinamics cerebrovascular o ka autoregulation a me ka hypoperfusion. ʻO kahi hōʻike MRI o CBF a hoʻololi i ka nui a me ka microvascular cerebral koko i ka wā o ka hemorrhagic hypotension. ʻOkelelo. 1999; 30: 2197-2204. [Hoʻokuʻuʻia]
- ʻO Zikopoulos B, ʻo Barbas H. i ka hāʻawi ʻana i ka nūnū thalamic reticular i kahi ala kūʻokoʻa no nā hana kuʻuna. J Neurosci. 2006; 26: 7348-7361. [Hoʻokuʻuʻia]